6721 - 6730 of 7877 Results
Title
Year
-
OPENTitle: CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 21Issue #: 3Start Page: 271End Page: 276Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2014.12.027Best OA location URL: https://europepmc.org/articles/pmc4603566?pdf=renderCitation Count: 84
-
OPENTitle: Sarcopenia and impairment in cognitive and physical performanceJournal Name: Clinical Interventions in AgingPublisher: Informa UK LimitedVol:Issue #:Start Page: 663End Page: 663Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.2147/cia.s76275Best OA location URL: https://www.dovepress.com/getfile.php?fileID=24358Citation Count: 88
- Chemogenomic Profiling of Endogenous PARK2 Expression Using a Genome-Edited Coincidence Reporter2015OPENTitle: Chemogenomic Profiling of Endogenous PARK2 Expression Using a Genome-Edited Coincidence ReporterJournal Name: ACS Chemical BiologyPublisher: American Chemical Society (ACS)Vol: 10Issue #: 5Start Page: 1188End Page: 1197Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1021/cb5010417Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927027Citation Count: 52
- Pharmacogenetics of Antipsychotic-Induced Movement Disorders as a Resource for Better Understanding Parkinson’s Disease Modifier Genes2015RESTRICTEDTitle: Pharmacogenetics of Antipsychotic-Induced Movement Disorders as a Resource for Better Understanding Parkinson’s Disease Modifier GenesJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 6Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2015.00027Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2015.00027/pdfCitation Count: 7
-
OPENTitle: Computational analysis of the LRRK2 interactomeJournal Name: PeerJPublisher: PeerJVol: 3Issue #:Start Page: e778End Page: e778Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.7717/peerj.778Best OA location URL: https://doi.org/10.7717/peerj.778Citation Count: 56
-
OPENTitle: Can Parkinson’s disease be cured by stimulating neurogenesis?Journal Name: Journal of Clinical InvestigationPublisher: American Society for Clinical InvestigationVol: 125Issue #: 3Start Page: 978End Page: 980Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1172/jci80822Best OA location URL: http://www.jci.org/articles/view/80822/files/pdfCitation Count: 10
-
RESTRICTEDTitle: Molecular imaging of levodopa-induced dyskinesiasJournal Name: Cellular and Molecular Life SciencesPublisher: Springer Science and Business Media LLCVol: 72Issue #: 11Start Page: 2107End Page: 2117Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s00018-015-1854-xCitation Count: 17
-
OPENTitle: Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer’s diseaseJournal Name: Acta NeuropathologicaPublisher: Springer Science and Business Media LLCVol: 129Issue #: 4Start Page: 565End Page: 583Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1007/s00401-015-1395-2Best OA location URL: https://link.springer.com/content/pdf/10.1007/s00401-015-1395-2.pdfCitation Count: 41
- Novel Antioxidants Protect Mitochondria from the Effects of Oligomeric Amyloid Beta and Contribute to the Maintenance of Epigenome Function2015OPENTitle: Novel Antioxidants Protect Mitochondria from the Effects of Oligomeric Amyloid Beta and Contribute to the Maintenance of Epigenome FunctionJournal Name: ACS Chemical NeurosciencePublisher: American Chemical Society (ACS)Vol: 6Issue #: 4Start Page: 588End Page: 598Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1021/cn500323qBest OA location URL: https://europepmc.org/articles/pmc4838453?pdf=renderCitation Count: 11
- Alpha1-chimaerin, a Rac1 GTPase-activating protein, is expressed at reduced mRNA levels in the brain of Alzheimer’s disease patients2015OPENTitle: Alpha1-chimaerin, a Rac1 GTPase-activating protein, is expressed at reduced mRNA levels in the brain of Alzheimer’s disease patientsJournal Name: Neuroscience LettersPublisher: Elsevier BVVol: 591Issue #:Start Page: 19End Page: 24Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neulet.2015.02.013Best OA location URL: https://europepmc.org/articles/pmc4382517?pdf=renderCitation Count: 11